REDWOOD CITY, Calif.,
May 22, 2015 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain, today announced that interim chief executive officer
Howie Rosen will be presenting at
Jefferies 2015 Healthcare Conference and chief financial officer
Tim Morris will be presenting at JMP
Securities Life Science Conference. Details of the two
presentations are as follows:
Jefferies 2015 Healthcare Conference
Date:
Monday June 1
Location: Grand Hyatt, New
York
Presentation Time: 4:00 pm ET,
1:00 pm PT
JMP Securities Life Science Conference
Date:
Wednesday June 24
Location: The St. Regis New York
Presentation Time: 9:00 am ET,
6:00 am PT
Presentations will be webcast live and can be accessed through
the Investors page at www.acelrx.com. For those not available
to listen to the live broadcast, a replay will be archived for 90
days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of acute and breakthrough pain.
AcelRx's lead product candidate, Zalviso™, is designed to improve
the management of moderate-to-severe acute pain in adult patients
in the hospital setting by utilizing a high therapeutic index
opioid, through a non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. AcelRx has announced positive
results from each of the three completed Phase 3 clinical trials
for Zalviso, has submitted an NDA to the FDA seeking approval for
Zalviso in the treatment of moderate-to-severe acute pain in adult
patients in the hospital setting and on July
25, 2014, received a Complete Response Letter (CRL) from the
FDA. In March 2015, AcelRx received
correspondence from the FDA stating that in addition to the bench
testing and two Human Factors studies AcelRx has performed to
address dispensing issues raised in the CRL, an additional clinical
trial is needed to assess the risk of inadvertent dispensing and
overall risk of dispensing failures. AcelRx has submitted a formal
meeting request to the FDA and this request has been denied and
AcelRx is evaluating its next steps with regards to the regulatory
process for Zalviso. In March 2015,
AcelRx initiated SAP301, a pivotal Phase 3 study for ARX-04, a
product candidate for the treatment of moderate-to-severe acute
pain in a medically supervised setting. SAP301 is now actively
enrolling. The Company has two additional pain treatment product
candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-june-300087679.html
SOURCE AcelRx Pharmaceuticals, Inc.